Vesugen

Khavinson tripeptide (Lys-Glu-Asp / KED) marketed as a "vascular bioregulator." Mechanism is thin (one DNA-binding-style hypothesis, same as pinealon), evidence is thin (one co-mention in a 5xFAD Alzheimer-mouse dendritic-spine paper where EDR/pinealon was the headline arm; otherwise monograph and vendor literature). Zero Western replication. Zero ClinicalTrials.gov entries. Khavinson family broad skepticism stands. Skip for now — the vascular-bioregulator framing is not earning its place in Dylan's stack against Cerebrolysin (brain), Semax/Adamax (brain), and the V4 antioxidant base (vascular adjacent). Only revisit if independent replication appears or vascular pathology develops.

Plain English: Vesugen is a 3-amino-acid peptide — lysine, glutamic acid, aspartic acid (KED). The Khavinson-group hypothesis is the same as for pinealon: small enough to slip past membranes and the nuclear envelope, then bind short DNA sequences in the promoters of "vascular" genes — turning transcription up or down like a few-key, few-lock system. The vendor / monograph framing is "vascular bioregulator" — claimed effects on endothelial regeneration, microcirculation, anti-fibrotic remodeling, and possibly on the NO / vasodilation axis. The specific gene-target list for KED is much less developed than the EDR/pinealon list (CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, GDX1) — most KED claims point at "vascular endothelium" as a tissue, not at specific named promoters.

Skeptical annotations:

1. Direct DNA binding (proposed, not independently confirmed). Same mechanism class as pinealon — and the same skeptical lens applies. Tripeptides do not generally have the binding specificity that proper transcription factors achieve via 50-300 amino-acid DNA-binding domains. Independent replication outside the Khavinson network has not occurred.
2. "Vascular bioregulator" claim is monograph-grade. The specific vascular endpoints (endothelial proliferation, NO axis, anti-fibrotic remodeling) are asserted in product literature and in Khavinson-group reviews, but the experimental backing is weaker than for pinealon. The framing comes mostly from product positioning, not from a hardened experimental program.
3. Pharmacokinetics mirror pinealon — minutes-long plasma half-life as expected for a tripeptide hydrolyzed by serum peptidases; oral bioavailability assumed but not independently characterized; no published human PK.
4. Active metabolite: None established. Constituent amino acids (Lys, Glu, Asp) themselves have biological activity but aren't claimed to mediate the KED-specific effects.